Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
Year: 2015
Type: letter
Abstract: We thank Pietrantonio et al , for their interest in our recent manuscript ( Rowland et al, 2015 ). We also acknowledge their mutual interest in the field, and share their goal of informing clinicians with the most accurate and complete evidence to ensure that patients with metastatic colorectal cancer (mCRC) are both afforded access and guided to the most appropriate treatment interventions.
Source: British Journal of Cancer
DOI: 10.1038/bjc.2015.325
Institutions: Flinders University, University of South Australia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W1727309928
